New hope for prostate cancer: Lower-Dose chemo combo shows promise
Disease control
Not yet recruiting
This study is for men with metastatic hormone-sensitive prostate cancer (mHSPC) that has spread. It tests a combination of darolutamide, hormone therapy (ADT), and a lower dose of the chemotherapy drug docetaxel. The goal is to see if this approach can make PSA levels undetectabl…
Phase: PHASE2 • Sponsor: Yonghong Li • Aim: Disease control
Last updated May 15, 2026 11:54 UTC